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OBJECTIVE: To investigate the frequencies and behavior of antiphospholipid antibodies in 57 children and adolescents
with systemic lupus erythematosus.
METHODS: Anticardiolipin antibodies were investigated by ELISA and lupus anticoagulant antibodies by the
international tests recommended. The antiphospholipid antibodies analyses were performed in frozen samples (mean of 5.3
samples per patient obtained during a mean follow-up period of 3 years and 7 months) and on blood samples collected
between January 1997 and November 1998 (mean of 2.5 samples per patient during a 2-year follow-up period).
RESULTS: The frequencies of antiphospholipid antibodies (anticardiolipin and lupus anticoagulant) were similar in
the samples collected prospectively and in the frozen samples (retrospective study): 63.2% and 75.4% respectively. Positivity
for these antibodies fluctuated during the follow-up period and was not associated with any clinical or laboratory parameters
of lupus erythematosus, including autoantibodies and also including disease activity and/or severity scores.
CONCLUSIONS: The frequencies of antiphospholipid antibodies in children and adolescents with lupus erythematosus
were similar to those observed in adults. The positivity fluctuated during the follow-up and was not correlated with clinical
and/or laboratory disease parameters.
DESCRIPTORS: Antiphospholipid antibodies. Children. Systemic lupus erythematosus.
The antiphospholipid (aPL) anti-
bodies constitute a heterogeneous fam-
ily of autoantibodies that react against
antigenic epitopes present in nega-
tively charged phospholipids, in com-
plex phospholipid-plasmatic proteins,
or even directly in plasmatic proteins1.
These antibodies are not always
pathogenic. They are present in sev-
eral situations, such as infections,
tumors, use of drugs, and even in 3%
to 4% of normal individuals, without
being related to thrombotic phenom-
ena2,3. The aPL antibodies can also be
detected in several autoimmune dis-
eases, for example, systemic lupus ery-
thematosus (SLE), Sjögren’s syndrome,
systemic sclerosis, eosinophilic
fasciitis, vasculitis, Behçet’s disease,
Lyme disease, sarcoidosis and rheuma-
toid arthritis4.
Antiphospholipid syndrome (APS)
is an entity characterized by the pres-
ence of arterial or venous thrombotic
phenomena or by the occurrence of
reccurented abortions associated with
the presence of antiphospholipid (aPL)
antibodies, positive on at least 2 oc-
casions5. In medical practice, only the
anticardiolipin antibodies (aCL) and
lupus anticoagulant (LAC) antibodies
are available for detecting the aPL an-
tibodies.
Only a few studies have evaluated
the frequency and behavior of the aPL
antibodies and the APS in children
with SLE. The positivity of the aPL
antibodies varies from 19% to 87%
(mean 56%) for the aCL antibodies and
from 11% to 62% (mean 31%) for LAC
antibodies. Antiphospholipid syn-
drome is present in 9% to 24% of the
cases6. Clinical manifestations relative
to the presence of aPL antibodies are
similar in children and adults, with a
prevalence of venous thrombosis.
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Table 1 - Frequency of antiphospholipid antibodies (aPL) in 57 children and adolescents with systemic lupus erythematosus
in the samples collected between January 1997 and November 1998.
anticardiolipin (aCL)
IgG IgM IgG and/or IgM LAC aPL
n (%) n (%) n (%) n/N (%) n (%)
1st sample (n=57) 6 (10.5) 18 (31.6) 20 (35.1) 7/52 (13.5) 23 (40.3)
2nd sample (n=48) 5 (10.4) 19 (39.6) 19 (39.6) 7/47 (14.9) 24 (50.0)
3rd sample (n=36) 1 (2.8) 13 (36.1) 13 (36.1) 2/21 (9.5) 13 (36.1)
+ in at least one sample (n = 57) 9 (15.8) 29 (50.9) 30 (52.6) 12/55 (21.8) 36 (63.2)
+ in two or more samples (n=48) 3 (6.2) 15 (31.2) 16 (33.3) 3/45 (6.7) 17 (35.4)
+ = positive for antibody; LAC = lupus anticoagulant antibody; n/N = number of positive samples / total number of samples.
This study was designed to evalu-
ate the frequency and behavior of aPL
antibodies in Brazilian children and
adolescents with SLE.
PATIENTS  AND  METHODS
A total of 57 children and adoles-
cents with SLE (according to the cri-
teria revised in 1982 by the American
College of Rheumatology7) were
evaluated from January 1997 to No-
vember 1998. The 57 children and
adolescents were selected from a sam-
ple of 109 patients with SLE that were
diagnosed at this service. The inclu-
sion criteria were the diagnosis of SLE
and correct follow-up (appointments,
laboratory tests, and treatment) be-
tween January 1997 and November
1998. Patients with more than 1 hos-
pitalization due to severe infectious
events were excluded.
The patients presented a mean age
of 14.7 years (range, 6 to 22 years) and
a female to male ratio of 5.3 to 1. The
mean age of disease onset was 10.2
years (range, 1 to 16 years).
The determination of the presence
of aPL antibodies was performed on
frozen samples obtained during a mean
follow-up period of 3 years, 7 months
(mean of 5.3 samples per patient,
range, 1 to 10 samples), collected at
patient admission, annually, and/or ac-
cording to clinical indication during
the course of the disease, as well as on
blood samples collected prospectively
(mean of 2.5 samples (range, 1 to 3) per
patient during a 2-year follow-up pe-
riod from January 1997 to November
1998).
The laboratory technique used for
all samples to detect the ACL antibody
was the enzyme-linked immunosor-
bent assay (ELISA) using the commer-
cial kit Hemagen Anticardiolipina®,
with results given in international
units (GPL and MPL). The values were
considered positive when above 10
GPL or 10 MPL. The following inter-
national recommendations8 were used
to detect the LAC antibodies in all the
samples: 3 screening tests were per-
formed (activated partial thromboplas-
tin time - aPTT, dilute Russell’s viper
venom test – DRVVT and kaolin clot-
ting time - KCT), and when indicated,
the confirmatory tests (PNP (platelet
neutralization procedure) of aPTT and/
or PNP of the DRVVT).
The evaluation of clinical and labo-
ratory manifestations and the disease
course was based on a retrospective
analysis of the records of each patient,
from admission to the end of the study
in November 1998. The activity of the
SLE was checked at the time of each
blood sample collection, based on the
erythrocyte sedimentation rate (ESR)
value and the systemic lupus ery-
thematosus disease activity index
(SLEDAI).
The statistical analysis was per-
formed using the chi-square test, Fish-
er’s exact test, t test for 2 independent
samples, Kruskal Wallis test, and
Cochran’s Q test, with statistical sig-
nificance established with a probabil-
ity of 95%. Spearman’s coefficient of
correlation was used for the correlation
analysis.
RESULTS
Of the 57 children and adolescents
with SLE studied, aPL antibodies were
positive in 63.2% and 75.4% of the
cases, respectively, in the samples col-
lected between January 1997 and No-
vember 1998 and in frozen samples
(retrospective analysis) (Tables 1 and
2). The number of samples collected
per patient varied from 1 to 3 (mean
2.5 samples per patient) in the 2-year
study and 1 to 10 (mean 5.3) in the ret-
rospective study.
Both analyses yielded similar re-
sults regarding positivity of the aPL an-
tibodies and their isotypes. Positivity
for aPL antibodies varied during the
study, being increased when only 1
sample was necessary to define this
positivity, as compared to the necessity
of 2 or more samples (Tables 1 and 2).
To relate the presence of aPL anti-
bodies, demographic data, and clinical
and laboratory manifestations, the fre-
quencies of aPL antibodies found in
the retrospective study (frozen sam-
ples) were used.
There was no significant difference
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Table 2 - Frequency of antiphospholipid antibodies (aPL) in 57 children and adolescents with systemic lupus erythematosus,
in at least 1 sample and in 2 or more samples, via retrospective analysis (mean follow up = 3.7 years).
anticardiolipin (aCL)
IgG IgM IgG and/or IgM LAC aPL
n (%) n (%) n (%) n/N (%) n (%)
+ in at least 1 sample (n = 57) 29 (50.9) 33 (57.9) 40 (70.2) 16/55 (29.1) 43 (75.4)
+ in 2 or more samples (n=54) 12 (22.2) 20 (37.0) 26 (48.1) 7/47 (14.9) 31 (57.4)
+ = positive for antibody; LAC = lupus anticoagulant antibody; n/N = number of positive samples / total number of samples.
Table 3 - Antiphospholipid antibodies (IgG and IgM anticardiolipin antibodies)
and demographic data in 57 children and adolescents with systemic lupus
erythematosus.
positive aPL negative aPL
n=43 n=14
AGE (mean/median) 15.1 / 14 13.6 / 16
AGE AT PRESENTATION (mean/median) 10.4 / 11 9.6 / 10
FOLLOW-UP (mean/median) 3.9 / 3 3.2 / 3
FEMALE:MALE RATE 36:7 12:2
CAUCASIANS 22 (51.2%) 4 (28.6%)
ADMIXTURE 16 (37.2%) 6 (42.8%)
NUMBER OF SAMPLES (mean/median) 5.6 / 6 4.1 / 4*
aPL = antiphospholipid antibodies; *P = 0.031
Table 4 - Antiphospholipid antibodies (IgG and IgM anticardiolipin antibodies)
and organs/systems involvement in 57 children and adolescents with systemic
lupus erythematosus
positive aPL negative aPL
n=43 n=14
n (%) n (%)
HEPATOMEGALY 18 (41.8) 1 (7.1)*
LIVEDO RETICULARIS 11 (25.6) 2 (14.3)
OSTEONECROSIS 2 (4.6) 0 (0)
VALVULITIS 10 (23.2) 2 (14.3)
HEMOLYTIC ANEMIA 17 (39.5) 6 (42.8)
THROMBOCYTOPENIA 12 (27.9) 3 (21.4)
HEADACHES 12 (27.9) 6 (42.8)
CHOREA 2 (4.6) 0 (0)
STROKES 3 (6.9) 4 (28.6)
PSYCHOSIS 3 (6.9) 0 (0)
VASCULAR CEREBRAL ACCIDENT 3 (6.9) 2 (14.3)
TRANSIENT ISCHEMIC ATTACKS 1 (2.3) 1 (7.1)
AMAUROSIS FUGAX 2 (4.6) 0 (0)
TRANSVERSE MYELITIS 1 (2.3) 0 (0)
COAGULATION ABNORMALITIES 9 (20.9) 0 (0)
BFP-STS 1 (2.3) 0 (0)
aPL = antiphospholipid antibodies; BFP-STS = biologic false positive serological test for syphilis;
*P = 0.021
between the group of patients with
positive aPL (n = 43) and the group of
patients with negative aPL (n = 14) in
terms of age, age at presentation, fol-
low-up, gender or race (Table 3). The
number of samples was higher in the
group that was positive for aPL (P =
0.031).
There was no association between
the presence of the aPL antibodies and
the involvement of any organs/systems
evaluated (Table 4), except in relation
to impairment of the reticuloendothe-
lial system, where a higher frequency
of hepatomegaly was observed in the
children and adolescents with SLE and
positive aPL antibodies (P = 0.021).
Regarding the disease activity, no
linear correlation was found between
the titers of IgG or IgM aCL antibod-
ies and the activity of SLE, when con-
sidering the mean titers of aCL anti-
bodies and mean values of ESR and
SLEDAI throughout the follow-up pe-
riod. A weak correlation (r = 0.38), al-
beit significant (P = 0.009), was ob-
served between the IgM aCL antibody
and the ESR levels when considering
only an isolated sample (the first) of
the 57 patients. Regarding the course
of the disease, remission was found
more frequently (P = 0.035) in the
group negative for aPL antibodies
when compared to the group present-
ing aPL antibodies (46.1% and 16.3%,
respectively).
Antiphospholipid syndrome was
diagnosed in 8 patients (14%) (Table
5). All patients presented positive IgG
aCL antibodies, 7 presented IgM aCL
antibodies, and 6 presented LAC anti-
bodies. Arterial events were found in
4 patients (ischemic vascular cerebral
accident (IVCA) - 3, amaurosis fugax
- 2, transient ischemic attack (TIA) - 1,
renal thrombosis - 1), and deep venous
thrombosis (DVP) – 1. Two patients
presented osteonecrosis, and transverse
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Table 5 - Characteristics of antiphospholipid syndrome (APS) in 8 patients with systemic lupus erythematosus (SLE).
CASE Thrombotic manifestations Other manifestations  related to APS Interval until the
diagnosis of APS, after
the diagnosis of SLE
1 IVCA hemolytic anemia, thrombocytopenia, livedo reticularis 3 yr 3 m
8 DVT (2x) hemolytic anemia, thrombocytopenia 3 yr 2 m
9 Renal thrombosis hemolytic anemia, thrombocytopenia, valvulitis 7 m
19 Osteonecrosis thrombocytopenia, migraine 5 yr 11 m
22 Amaurosis fugax, TIA, IVCA (2x) hemolytic anemia, thrombocytopenia, behavioral disturbances 6 m
24 Osteonecrosis hemolytic anemia, thrombocytopenia, migraine 3 yr 7m
26 Amaurosis fugax, IVCA hemolytic anemia, thrombocytopenia, migraine 2 yr 11m
49 Transverse myelitis - 3 yr 10m
IVCA= ischemic vascular cerebral accident; TIA= transient ischemic attack; DVT = deep venous thrombosis
myelitis was found in the last one.
Three patients presented more than 1
event (mean interval of 13 months be-
tween them). Hemolytic anemia and
thrombocytopenia were found in 6 and
7 patients, respectively. Other manifes-
tations related to APS found in these
patients included headaches (3), val-
vulitis (1), behavioral disturbances (1)
and livedo reticularis (1). The interval
between SLE and APS diagnosis was
3 years (ranging from 6 months and 5
years, 11 months).
DISCUSSION
In this study, the frequencies of aPL
antibodies presented a very well-de-
fined behavior. The number of indi-
viduals positive for aPL antibodies on
at least 1 occasion was larger than the
number of individuals positive on 2 or
more occasions. This fact was observed
both in the samples collected between
January 1997 and November 1998
(63.2% and 35.4%, respectively) and
in the frozen samples (retrospective
study) (75.4% and 57.4%, respectively)
for aCL antibodies and LAC antibo-
dies, which suggest a cyclical behavior
of these autoantibodies.
Several works have verified that
the positivity of the aPL antibodies is
linked to the time of follow-up and the
number of times that it is tested9;10;11.
PÉREZ-VÁZQUEZ et al.10 demon-
strated that when they extended the
follow-up of a group of 667 lupus pa-
tients from 7.5 months to 3.1 years, the
frequency of aPL antibodies increased
from 52% to 66%, with a consequent
increase in the number of cases in
which it was possible to diagnose APS
(from 10% to 15%).
Regarding the isotypes, the aCL
antibody was detected more frequently
than the LAC antibody (52.6% and
21.8%, respectively, in the samples
collected in the 2-year study and
70.2% and 29.1% in the retrospective
study – frozen samples). This finding
is in agreement with data reported in
literature, where the positivity for aPL
antibodies among lupus children var-
ies from 19% to 87% (mean 56%) for
the aCL antibody and from 11% to
62% (mean 31%) for LAC antibodies6.
The IgM aCL isotype was found
more frequently than the IgG aCL
isotype in both analyses. This differ-
ence was maintained when we selected
the patients that were positive on 2 or
more occasions. In the literature, the
IgG isotype is reported to be the most
common in adults and children with
lupus12.The clinical manifestations re-
lated to the presence of aPL antibod-
ies in children are similar to those
found in adults, in agreement with the
literature review performed by Ravelli
& Martini in 19976.
In this study, the presence of the
aPL antibodies was not correlated with
a specific clinical or laboratory profile
among the children and adolescents
studied. Hepatomegaly was the only
manifestation that was statistically
more frequent in the group with posi-
tive aPL antibodies. In the literature,
there are reports of patients with APS,
hepatomegaly, and an increase in the
hepatic enzymes, which is attributed
to hepatic microthrombosis without
any relationship to infections, drugs,
congestion, and degenerative or meta-
bolic causes 13. In this study, the chil-
dren that presented hepatomegaly as-
sociated with the presence of aPL an-
tibodies (n = 18) did not present any
other clinical or laboratory manifesta-
tions of hepatic abnormality. All the
patients, except 3, presented other
signs of involvement of the reticuloen-
dothelial system, such as adenomegaly
(n = 14) and/or splenomegaly (n = 6).
Other manifestations usually re-
ported in the literature in association
with the aPL antibodies, such as livedo
reticularis, osteonecrosis, valvulitis,
hemolytic anemia, and thrombocyto-
penia, were also not found frequently
in this study. Even involvement of the
central nervous system (with manifes-
tations such as headaches, strokes,
transient ischemic attacks, amaurosis
fugax, psychosis, chorea, and trans-
verse myelitis), which in the studies by
RAVELLI et al. 12 and SHERGY et al.
14 was reported to be associated with
the presence of aPL antibodies, was
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not observed in the patients of this
study. Coagulation abnormalities,
characterized by prolongation of the
prothrombin time and/or activated
partial thromboplastin time, were only
found in the patients with positive aPL
antibodies (20.9%) and in none of the
patients with negative aPL antibodies.
The low frequency of these abnormali-
ties indicates the low sensitivity of
these parameters as screening methods
for the detection of aPL antibodies, as
has already been observed by PETRI
2. The same is true in relation to the
biologic false-positive serological test
for syphilis (BFP-STS) that was found
in just 1 patient with positive aPL an-
tibodies.
In the studies by RAVELLI et al. 12
and SHERGY et al. 14 in children with
SLE, it can be seen that the positivity
of the aPL antibodies fluctuated during
the follow-up. RAVELLI et al. 12 dem-
onstrated a relationship between the
titers of the aCL antibody and disease
activity when the ESR, the reduction in
the C3 fraction of the complement, and
Systemic Lupus Activity Measure
(SLAM) were analyzed, but this corre-
lation was not maintained when
SLEDAI and anti-DNA antibody were
used as parameters of disease activity.
In this study, it was observed that
fewer patients with positive aPL anti-
bodies tended to experience disease
remission, when compared to patients
with negative aPL antibodies (P =
0.035). It is possible that patients with
a remittent disease course produce
fewer autoantibodies and consequently
present a lower frequency of aPL anti-
bodies.
This study, and its similarity to oth-
ers in the literature, presents some in-
teresting aspects.
The behavior of the aPL antibod-
ies was cyclical in terms of positivity,
with a higher frequency in the longer
periods of follow-up and/or larger
number of samples collected. There
was no clear relationship of the occur-
rence of aPL antibodies with disease
activity, severity, or clinical and labo-
ratory manifestations. It is possible that
their occurrence has a relationship
with the etiopathic mechanism of the
SLE itself (production of multiple
autoantibodies) or with the appearance
of neoantigens due to the process of
chronic vasculitis or also due to the
chronic use of corticosteroids, causing
abnormalities in lipid metabolism.
This second hypothesis (exposure to
neoantigens) could explain the late
emergence of the manifestations re-
lated to the aPL antibodies during the
follow-up of patients with SLE.
There was also no correlation be-
tween the presence of aPL antibodies
and specific clinical manifestations,
which does not support a pathogenic
role for these antibodies. It is possible
that there are pathogenic aPL antibod-
ies and nonpathogenic aPL antibodies,
which would explain the high fre-
quency of patients with SLE that have
aPL antibodies and the low relative
frequency of APS in these patients. In
fact, various authors have suggested
that the pathogenic aPL antibodies
could be those dependent on the β2-
GP13;15. While studying the aCL and
anti-β2-GP1 antibodies in patients
with SLE, AMENGUAL et al.15 ob-
served that the former were present in
70.4% of the cases with APS and in
24.5% of the patients without APS,
while the anti-β2-GP1 were present in
53.5% and 4.1%, respectively. Thus,
the anti-β2-GP1 antibody was more
specific, while being less sensitive. Pa-
tients that are positive for aCL anti-
bodies and negative for anti-β2-GP1
antibodies could correspond to the
cases in which the aCL antibodies are
independent from the β2-GP1 and are
therefore nonpathogenic, or also
pathogenic, through the connection
with other plasmatic proteins. Further
studies with the intention of identify-
ing the pathogenic role of the aPL an-
tibodies and their connection with
specific plasmatic proteins will be im-
portant to establish the real role of aPL
antibodies in patients with SLE.
RESUMO
CAMPOS LMA e col. - Anticorpos
antifosfolípides em 57 crianças e
adolescentes com lúpus eritema-
toso sistêmico. Rev. Hosp. Clín.
Fac. Med. S. Paulo 58(3):157-162,
2003.
OBJETIVO: Investigar a freqüên-
cia e o comportamento dos anticorpos
antifosfolípides em 57 crianças e ado-
lescentes com lúpus eritematoso sistê-
mico.
MÉTODOS: A técnica laboratorial
para a pesquisa do anticorpo anticar-
diolipina foi ELISA e para a pesquisa
do anticorpo anticoagulante lúpico fo-
ram seguidas as recomendações inter-
nacionais. A pesquisa dos anticorpos
antifosfolípides foi realizada em soros
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estocados (média de 5,3 amostras por
paciente durante o período de segui-
mento de em média 3 anos e 7 meses)
e em soros coletados no período de ja-
neiro de 1997 à novembro de 1998
(média de 2,5 amostras por paciente
em um período de dois anos).
RESULTADOS: A freqüência dos
anticorpos antifosfolípides (anticorpo
anticardiolipina e anticoagulante
lúpico) foi semelhante nos soros
coletados prospectivamente e nos so-
e adolescentes com lúpus eritematoso
sistêmico foi semelhante à observada
em adultos. A positividade dos anti-
corpos flutuou durante o seguimento
dos pacientes e não foi evidenciada
associação com parâmetros clínicos e/
ou laboratoriais da doença.
DESCRITORES: Anticorpos anti-
fosfolípides. Crianças. Lúpus erite-
matoso sistêmico.
ros estocados (estudo retrospectivo):
63,2% e 75,4% respectivamente. A
positividade destes anticorpos flutuou
durante o seguimento e não esteve as-
sociado a nenhum parâmetro clínico e
laboratorial do lúpus eritematoso
sistêmico, incluindo auto-anticorpos e
também atividade e/ou gravidade da
doença.
CONCLUSÕES: A freqüência dos
anticorpos antifosfolípides em crianças
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